Abstract
Alzheimers disease (AD) leads to a dramatic decline in cognitive abilities and memory. A more modest disruption of memory often occurs in normal aging and the same circuits that are devastated through degeneration in AD are vulnerable to sub-lethal age-related changes that alter synaptic transmission. There are numerous indications that aberrant plasticity is critically involved in Alzheimers. Is ageing itself the major risk factor for AD? Is AD an acceleration of normal ageing? We assume that the ability of the brain is to modify its own structural organization and functioning which is liable to become impaired in ageing until it becomes dramatically impaired in Alzheimers. Moreover, ageing can compromise the conversion of dietary alpha-linolenic acid (ALA) to docosahexaenoic acid (DHA). DHA regulates synaptogenesis and affects the synaptic structure, and synapse density is reduced in ageing. DHA and newly identified DHAderived messenger, neuroprotecting D1 (NPD1), protect synapses and decrease the number of activated microglia in the hippocampal system. Delaying AD onset by a few years would reduce the number of the cases of dementia in the community. DHA (and NPD1?) and aspirin induce brain-derived neurotrophic factor (BDNF) protein expression and this protein has a crucial role in neuronal survival. The authors – in view of the increased neuroinflammatory reaction frequently observed during normal brain ageing - suggest the long-term use of “fatty aspirin”, an association of DHA and/or NPD1 and aspirin (or nitroaspirin), to postpone, or prevent, the structural neurodegeneration of the brain.
Keywords: Alzheimer's prevention, docosahexaenoic acid, synaptogenesis, aspirin, microglia
Current Alzheimer Research
Title: Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Volume: 5 Issue: 5
Author(s): Massimiliano Pomponi, Annamaria Di Gioia, Pietro Bria and Massimo Fabio Lucio Pomponi
Affiliation:
Keywords: Alzheimer's prevention, docosahexaenoic acid, synaptogenesis, aspirin, microglia
Abstract: Alzheimers disease (AD) leads to a dramatic decline in cognitive abilities and memory. A more modest disruption of memory often occurs in normal aging and the same circuits that are devastated through degeneration in AD are vulnerable to sub-lethal age-related changes that alter synaptic transmission. There are numerous indications that aberrant plasticity is critically involved in Alzheimers. Is ageing itself the major risk factor for AD? Is AD an acceleration of normal ageing? We assume that the ability of the brain is to modify its own structural organization and functioning which is liable to become impaired in ageing until it becomes dramatically impaired in Alzheimers. Moreover, ageing can compromise the conversion of dietary alpha-linolenic acid (ALA) to docosahexaenoic acid (DHA). DHA regulates synaptogenesis and affects the synaptic structure, and synapse density is reduced in ageing. DHA and newly identified DHAderived messenger, neuroprotecting D1 (NPD1), protect synapses and decrease the number of activated microglia in the hippocampal system. Delaying AD onset by a few years would reduce the number of the cases of dementia in the community. DHA (and NPD1?) and aspirin induce brain-derived neurotrophic factor (BDNF) protein expression and this protein has a crucial role in neuronal survival. The authors – in view of the increased neuroinflammatory reaction frequently observed during normal brain ageing - suggest the long-term use of “fatty aspirin”, an association of DHA and/or NPD1 and aspirin (or nitroaspirin), to postpone, or prevent, the structural neurodegeneration of the brain.
Export Options
About this article
Cite this article as:
Pomponi Massimiliano, Gioia Di Annamaria, Bria Pietro and Lucio Pomponi Fabio Massimo, Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?, Current Alzheimer Research 2008; 5 (5) . https://dx.doi.org/10.2174/156720508785908892
DOI https://dx.doi.org/10.2174/156720508785908892 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology Metabolic Syndrome and Cognitive Decline
Current Alzheimer Research Assessing the Relationship between Health Utilities, Quality of Life, and Health Care Costs in Alzheimers Disease: The CATIE-AD Study
Current Alzheimer Research Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [<sup>11</sup>C]PK11195 and [<sup>11</sup>C]vinpocetine
Current Radiopharmaceuticals Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls
Current Alzheimer Research Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Recent Developments in Computer Aided Diagnosis for Lung Nodule Detection from CT images: A Review
Current Medical Imaging Diagnostic and Prognostic Potential of Retinal Biomarkers in Early On-Set Alzheimer’s Disease
Current Alzheimer Research Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease
CNS & Neurological Disorders - Drug Targets Glycine Transporter 1 Inhibitors and Modulation of NMDA Receptor-Mediated Excitatory Neurotransmission
Current Drug Targets Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets Chinese Medicinal Herbs as Source of Antioxidant Compounds – Where Tradition Meets the Future
Current Medicinal Chemistry Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Herbal Medicine for Vascular Dementia: An Overview of Systematic Reviews
Current Vascular Pharmacology Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) Drosophila Models of Proteinopathies: the Little Fly that Could
Current Pharmaceutical Design